Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Children
NCT02153112Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2015
- Primary completion
- Jun 2018
- Modality
- Recombinant Protein Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of NoV GI.1/GII.4 bivalent VLP vaccine in norovirus infection, sponsored by Takeda. Started Jun 2015; status: completed.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT02153112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153112.